Xiaobo Bo
Impact in
-
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
-
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
Papers in
- Co-authors
- Yueqi Wang (18 shared papers)Houbao Liu (16 shared papers)Jie Wang (11 shared papers)Changcheng Wang (11 shared papers)Tao Suo (12 shared papers)Sheng Shen (10 shared papers)Xiaoling Ni (10 shared papers)Jie Wang (2 shared papers)
- Journals
- Cancer Science (3 papers)Oncotarget (2 papers)Frontiers in Oncology (2 papers)Clinical and Translational Medicine (2 papers)Surgical Endoscopy (2 papers)
- Partner nations
- China
In The Last Decade
Xiaobo Bo
23 papers receiving 286 citations
Peers
Comparison fields: 5 of 37
- Cancer Research 58
- Oncology 80
- Surgery 115
- Pulmonary and Respiratory Medicine 56
- Immunology 37
Countries citing papers authored by Xiaobo Bo
This map shows the geographic impact of Xiaobo Bo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobo Bo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobo Bo more than expected).
Fields of papers citing papers by Xiaobo Bo
This network shows the impact of papers produced by Xiaobo Bo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobo Bo. The network helps show where Xiaobo Bo may publish in the future.
Co-authors
The 25 scholars most cited alongside Xiaobo Bo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 49 | |
| 2 | MiR-146a suppresses hepatocellular carcinoma by downregulating TRAF6. | 2016 | 35 |
| 3 | 2019 | 27 | |
| 4 | 2018 | 24 | |
| 5 | 2022 | 19 | |
| 6 | 2018 | 17 | |
| 7 | 2019 | 12 | |
| 8 | 2021 | 12 | |
| 9 | 2019 | 12 | |
| 10 | 2020 | 11 | |
| 11 | 2019 | 10 | |
| 12 | 2020 | 10 | |
| 13 | 2021 | 8 | |
| 14 | 2017 | 7 | |
| 15 | 2017 | 6 | |
| 16 | 2018 | 6 | |
| 17 | 2017 | 6 | |
| 18 | 2024 | 5 | |
| 19 | 2022 | 5 | |
| 20 | 2021 | 3 |
About Xiaobo Bo
Xiaobo Bo is a scholar working on Surgery, Oncology, Molecular Biology, Cancer Research and Immunology, having authored 24 papers that have together received 290 indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers), MicroRNA in disease regulation (4 papers), Inflammatory Biomarkers in Disease Prognosis (3 papers), Circular RNAs in diseases (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cancer-related molecular mechanisms research (3 papers), Cancer Mechanisms and Therapy (1 paper) and Ubiquitin and proteasome pathways (1 paper). The work is most often cited by research in Cancer Research (58 citations), Oncology (80 citations), Surgery (115 citations), Pulmonary and Respiratory Medicine (56 citations) and Immunology (37 citations). Xiaobo Bo has collaborated with scholars based in China. Frequent co-authors include Yueqi Wang, Houbao Liu, Jie Wang, Changcheng Wang, Tao Suo, Sheng Shen, Xiaoling Ni, Jie Wang, Jingquan Li and Peizhan Chen. Their work appears in journals such as Cancer Science, Oncotarget, Frontiers in Oncology, Clinical and Translational Medicine and Surgical Endoscopy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.